CNE100002FV6
CNE100002FV6
SHANDONG BUCHANG PHARMACEUTICAL
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 85/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±30.9% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.3x).
Beta (Market Relation)
0.29x
DefensiveVolatility (5Y p.a.)
30.9% p.a.
5-Year HorizonMax Drawdown (5Y)
-47.9%
5-Year HorizonSharpe Ratio
-0.24
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -18.9% |
| 3 Years | 25.1% | -28.2% | -0.31 | -5.3% |
| 5 Years | 30.9% | -47.9% | -0.24 | -4.6% |
| 10 Years | 32.5% | -83.4% | -0.42 | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 64.4 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -83.4% in the extended horizon.